gamma-aminobutyric acid has been researched along with Hyperesthesia in 8 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Hyperesthesia: Increased sensitivity to cutaneous stimulation due to a diminished threshold or an increased response to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ability of bicuculline to alleviate allodynia and formalin-evoked hyperalgesia in diabetic rats is consistent with a reversal of the properties of GABA predicted by reduced spinal KCC2 and suggests that reduced KCC2 expression and increased GABA release contribute to spinally mediated hyperalgesia in diabetes." | 1.35 | Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transporters. ( Calcutt, NA; Jolivalt, CG; Lee, CA; Ramos, KM, 2008) |
| "Both thermal hyperalgesia and tactile allodynia were reversed when transplants were placed either one or two weeks after partial nerve injury, compared to maintenance of these behaviors with the injury alone." | 1.31 | Only early intervention with gamma-aminobutyric acid cell therapy is able to reverse neuropathic pain after partial nerve injury. ( Cejas, P; Eaton, MJ; Karmally, S; Lopez, T; Martinez, MA; Stubley, LA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haribabu, PK | 1 |
| Eliav, E | 1 |
| Heir, GM | 1 |
| Jolivalt, CG | 1 |
| Lee, CA | 1 |
| Ramos, KM | 1 |
| Calcutt, NA | 1 |
| Masa-Vázquez, LA | 1 |
| Villamil-Cajoto, I | 1 |
| Villar Del Castillo, A | 1 |
| Takazawa, T | 1 |
| MacDermott, AB | 1 |
| Sakai, Y | 1 |
| Nishijima, Y | 1 |
| Mikuni, N | 1 |
| Iwata, N | 1 |
| Cui, JG | 1 |
| Meyerson, BA | 1 |
| Sollevi, A | 1 |
| Linderoth, B | 1 |
| Stubley, LA | 1 |
| Martinez, MA | 1 |
| Karmally, S | 1 |
| Lopez, T | 1 |
| Cejas, P | 1 |
| Eaton, MJ | 1 |
| Robinson, A | 1 |
| Tannier, C | 1 |
| Magnaval, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Single Blinded, Randomized Control Trial of High Frequency Stimulation in Subjects With Precision® Spinal Cord Stimulator System to Assess Efficacy and Preferability in Back and Extremity Pain Relief[NCT02265848] | Phase 4 | 22 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Identification of Differentially Expressed Genes in RNAseq Data of Patients With Failed Back Surgery Syndrome Treated With Different Modalities of Spinal Cord Stimulation: Looking for Biomarkers of Response and Effectiveness[NCT05712980] | 40 participants (Anticipated) | Observational | 2023-02-28 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Digital pain rating system that scores patient's subjective pain rating from 0 to 10; with greater number indicating progressively worsening pain. NPRS were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Average Baseline NPRS Score | Average NPRS after 1000 Hz. stimulation | Average NPRS after standard stimulation | Average NPRS after Wash off | Best Baseline NPRS score | Best NPRS score after 1000 Hz. stimulation | Best NPRS score after standard stimulation | Best NPRS after Wash off | Worst Baseline NPRS score | Worst NPRS score after 1000 Hz. stimulation | Worst NPRS score after standard stimulation | Worst NPRS after Wash off | |
| Treatment Group A | 6.09 | 3.73 | 5.64 | 6.45 | 3.72 | 2.64 | 3.46 | 4.54 | 7.90 | 6.64 | 8.18 | 8.72 |
| Treatment Group B | 6.27 | 3.82 | 6.09 | 7.18 | 4.45 | 2.18 | 4.45 | 5.36 | 8.09 | 6.64 | 8.36 | 8.81 |
ODI is a outcome metrics that is design to assess the severity of disability based on 10 activity categories. ODI is based on 0 to 100% scale, where larger percentage implies worse disability. (There are 5 categories: 0-20%: Minimal disability, 21-40%: Moderate disability, 41-60%: Severe disability, 61-80%: Crippled. 81-100%: Either bed bound or exaggerating symptoms). ODI were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline ODI score | ODI after 1000 Hz. stimluation | ODI after standard stimulation | ODI after wash off | |
| Treatment Group A | 47.49 | 39.23 | 49.63 | 52.87 |
| Treatment Group B | 51.25 | 33.77 | 49.05 | 56.77 |
PGIC is a 7-point scale that requires study subjects to rate the severity of their illness or medical condition after a specific treatment. 1: No change, 2: Almost the same, 3: A little better, 4: Somewhat better, 5: Moderately better, 6: Better, 7: A great deal better. Study subjects were asked to report their impression of changes at baseline visit, visit 2 through 4. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| PGIC After 1000 Hz. stimulation | PGIC after standard stimulation | PGIC after Wash off | |
| Treatment Group A | 4.27 | 2.54 | 1.45 |
| Treatment Group B | 5.91 | 2.45 | 1.27 |
At the conclusion of the study, subjects were asked to report which spinal cord stimulation modes they preferred. Subjects were presented with two boxes (1000 Hz. stimulation and Standard stimulation) and asked to check one. (NCT02265848)
Timeframe: End of treatment visit on visit 4
| Intervention | participants (Number) | |
|---|---|---|
| Subjects who prefer 1000 Hz. stimulation | Subjects who prefer standard stimulation | |
| Treatment Group A | 8 | 3 |
| Treatment Group B | 10 | 1 |
8 other studies available for gamma-aminobutyric acid and Hyperesthesia
| Article | Year |
|---|---|
Topical medications for the effective management of neuropathic orofacial pain.
Topics: Administration, Topical; Amines; Analgesics, Non-Narcotic; Anesthetics, Local; Anti-Inflammatory Age | 2013 |
Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transporters.
Topics: Animals; Diabetes Mellitus, Experimental; gamma-Aminobutyric Acid; Hyperalgesia; Hyperesthesia; K Cl | 2008 |
Efficacy and safety of pregabalin in neuropathic pain treatment: a still unreported adverse effect.
Topics: Adult; Analgesics; Bronchial Spasm; Female; gamma-Aminobutyric Acid; Humans; Hyperesthesia; Hypesthe | 2008 |
Synaptic pathways and inhibitory gates in the spinal cord dorsal horn.
Topics: Afferent Pathways; Animals; Electric Stimulation; Evoked Potentials; gamma-Aminobutyric Acid; Hypere | 2010 |
Inhibitory mechanisms of the hyper-irritability caused by picrotoxin in the rat.
Topics: Animals; Brain; Dopamine; Dose-Response Relationship, Drug; Electric Stimulation; Electromyography; | 1981 |
Effect of spinal cord stimulation on tactile hypersensitivity in mononeuropathic rats is potentiated by simultaneous GABA(B) and adenosine receptor activation.
Topics: Adenosine; Animals; Baclofen; Electric Stimulation; GABA Agonists; GABA Antagonists; gamma-Aminobuty | 1998 |
Effect of spinal cord stimulation on tactile hypersensitivity in mononeuropathic rats is potentiated by simultaneous GABA(B) and adenosine receptor activation.
Topics: Adenosine; Animals; Baclofen; Electric Stimulation; GABA Agonists; GABA Antagonists; gamma-Aminobuty | 1998 |
Effect of spinal cord stimulation on tactile hypersensitivity in mononeuropathic rats is potentiated by simultaneous GABA(B) and adenosine receptor activation.
Topics: Adenosine; Animals; Baclofen; Electric Stimulation; GABA Agonists; GABA Antagonists; gamma-Aminobuty | 1998 |
Effect of spinal cord stimulation on tactile hypersensitivity in mononeuropathic rats is potentiated by simultaneous GABA(B) and adenosine receptor activation.
Topics: Adenosine; Animals; Baclofen; Electric Stimulation; GABA Agonists; GABA Antagonists; gamma-Aminobuty | 1998 |
Only early intervention with gamma-aminobutyric acid cell therapy is able to reverse neuropathic pain after partial nerve injury.
Topics: Animals; Cell Transplantation; gamma-Aminobutyric Acid; Hot Temperature; Hyperalgesia; Hyperesthesia | 2001 |
[Toxocara canis meningoradiculitis].
Topics: Acetates; Adrenal Cortex Hormones; Aged; Amines; Analgesics, Opioid; Animals; Anti-Inflammatory Agen | 2002 |